TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18428023
Drug: Acute insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute insulin response (AIR)
Study: 16132058
Drug: 250 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml/day of Sicilian red wine for 4 weeks
Study: 10838463
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet + resistance exercise + casein protein (1.5 g/kg/day)
Study: 23834666
Drug: BAX326 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX326 (recombinant factor IX); Dosage: 49.5 (±4.8) IU kg(‐1) per infusion, administered twice weekly for a mean duration of 6.2 (±0.7) months
Study: 23834666
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (on-demand treatment)
Study: 20070299
Drug: 1-year maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1-year maintenance after a 6-week cycle of early intravesical chemotherapy (epirubicin, 80 mg/50 mL)
Study: 20070299
Drug: Maintenance regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance regimen with monthly instillations for 1 year
Study: 17445330
Drug: Outreach intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outreach intervention for providers and CBD agents
Study: 17445330
Drug: Provider-based activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-based activities with concurrent demand creation activities
Study: 16199428
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle)
Study: 16199428
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of rosiglitazone and EE/CPA
Study: 12955342
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy for mild incontinence
Study: 12955342
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy for moderate incontinence
Study: 9537132
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (0.2 mg/ml, 0.02%)
Study: 8182273
Drug: Formalin‐inactivated, alum‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (VAQTA)
Study: 3802604
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (ISDN) 5 mg
Study: 28468077
Drug: Jitai tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablet
Study: 28468077
Drug: Jitai tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitai tablet plus buprenorphine
Study: 23774044
Drug: Myofascial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial treatment in the masseter and temporalis muscles
Study: 19808138
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of levofloxacin 500 mg
Study: 17034283
Drug: Yunzhi-Danshen capsules
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunzhi-Danshen capsules (3.6 g Yunzhi and 1.4 g Dangshem daily for 16 weeks)
Study: 17034283
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 capsules daily for 16 weeks)
Study: 17034283
Drug: Yunzhi-Danshen capsules
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunzhi-Danshen capsules
Study: 15073259
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg rhTSH
Study: 15073259
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg rhTSH
Study: 2945811
Drug: Teicoplanin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (0.2 g)
Study: 2945811
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g)
Study: 28805281
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and Caffeine 100 mg
Study: 24837773
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of MMR at 8 months
Study: 24837773
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of MMR at 12 months
Study: 24837773
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after first dose of MMR
Study: 24837773
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after second dose of MMR
Study: 22257994
Drug: Chlorhexidine-based skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-based skin preparation solution
Study: 22257994
Drug: Iodine-based skin
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine-based skin preparation solution
Study: 20483888
Drug: Electronic metronome
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (early group)
Study: 20483888
Drug: Electronic metronome
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (late group)
Study: 11792137
Drug: tirofiban +
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban + heparin
Study: 10367823
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1600 microg/d for 21 days)
Study: 7739681
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (group 3)
Study: 2199866
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g intravenously)
Study: 2199866
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g intravenously)
Study: 7028047
Drug: Ciclopiroxolamine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine cream
Study: 26325026
Drug: CogniPlus method
Approvals — FDA: no, EMA: no, PMDA: no
Description: CogniPlus method with dynamic balance training (20 cognitive training sessions twice per week for 10 weeks)
Study: 15033676
Drug: Non-5-FU chemotherapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-5-FU chemotherapy (cis/carboplatin, anthracycline, cyclophosphamide)
Study: 15033676
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) with glyceroltrinitrate pre-treatment
Study: 15033676
Drug: Non-5-FU chemotherapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-5-FU chemotherapy
Study: 7749824
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.4 g daily)
Study: 7749824
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil with vitamin E (2.4 g daily)
Study: 2261209
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Idarubicin
Study: 2261209
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Idarubicin under non-fasting conditions
Study: 31068015
Drug: Adjunctive chronotype-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive chronotype-based bright light therapy (30 minutes a day for 3 weeks, illuminance: 4246 lux, irradiance: 1802.81 µW.cm‐2)
Study: 31068015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with multimodal psychiatric treatment
Study: 18832520
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) 3 g mesalazine granules
Study: 18832520
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily (TID) 1 g mesalazine granules
Study: 14739800
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 150 mmHg
Study: 14739800
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 300 mmHg
Study: 15848976
Drug: Sugar-free chewing
Normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free chewing gum in addition to oral health education (Group G)
Study: 15848976
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education (Group E)
Study: 1959195
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg and 10 mg twice daily
Study: 1959195
Drug: Nisoldipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 2.5 mg, 5 mg, 10 mg twice daily
Study: 1959195
Drug: Nisoldipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 2.5 mg and 5 mg twice daily
Study: 30383184
Drug: Durvalumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4 weeks for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks))
Study: 30383184
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg every 2 weeks) monotherapy
Study: 30383184
Drug: Tremelimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (10 mg/kg every 4 weeks for 7 doses then every 12 weeks for 2 doses) monotherapy
Study: 8062939
Drug: Cetrorelix 5
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 5 mg (group 1)
Study: 8062939
Drug: Cetrorelix 3
Normalized name: cetrorelix 3 mg subcutaneous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 3 mg (group 2)
Study: 29648859
Drug: Alliance focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alliance focused therapy
Study: 27062069
Drug: Group psychotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychotherapy + lodenafil 80 mg/one tablet per week (Group 4)
Study: 27062069
Drug: Lodenafil 80
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil 80 mg/one tablet per week (Group 3)
Study: 20568384
Drug: Montelukast, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 5 mg
Study: 18294411
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg kg(‐1) over 10 min at anaesthesia induction followed by 0.4‐0.8 microg kg(‐1) h(‐1) infusion during maintenance
Study: 18294411
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg kg(‐1) over 1 min at anaesthesia induction followed by 0.2‐0.4 microg kg(‐1) min(‐1) infusion during maintenance
Study: 16274834
Drug: ISIS 14803
Normalized name: ISIS 14803
DrugBank: ISIS 14803 (DB05803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 14803 (0.5-3 mg/kg, thrice weekly for 4 weeks)
Study: 11030202
Drug: 1-week course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week course of oral prednisolone (PSL, 0.5 mg/kg)
Study: 11030202
Drug: 2-week course
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week course of oral prednisolone (PSL, 0.5 mg/kg)
Study: 3818148
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg plus Ranitidine 150 mg
Study: 29972003
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (before and after treatment)
Study: 21280296
Drug: Antistax at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antistax at a daily dose of 360 mg
Study: 21280296
Drug: Antistax at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antistax at a daily dose of 720 mg
Study: 16104439
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isobaric ropivacaine
Study: 16104439
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg isobaric ropivacaine plus 25 microg fentanyl
Study: 12005465
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of standard parenteral nutrition (1.5-liter HPN formula, infused over 10 hours, approximately 25 kcal/kg/d with 30% lipid and 1.0 to 1.5 g/kg/d of protein)
Study: 12005465
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of standard parenteral nutrition
Study: 7770303
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg every 6 hours for 4 days)
Study: 2180230
Drug: Live Shigella
Normalized name: Shigella dysenteriae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Shigella flexneri 2a and Shigella sonnei vaccine candidate strains with two virulence‐reducing markers
Study: 2180230
Drug: Ultrasonic lysates
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic lysates of vaccine candidate strains
Study: 31977888
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (CCR) 3 times a week for 8 weeks plus neurologic music therapy (NMT) techniques, performed 3 times a week for 8 weeks.
Study: 27405522
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment in groups for 1 year
Study: 27405522
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment in groups
Study: 25055821
Drug: Prucalopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2 mg once daily) for 32 weeks
Study: 19505393
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sublingual‐swallow therapy (SLIT)
Study: 12410756
Drug: Desmopressin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin therapy (with or without anticholinergic agents)
Study: 12410756
Drug: NDE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDE group (therapy‐resistant enuresis)
Study: 29650683
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 days 1, 4, and 7
Study: 18928735
Drug: Comprehensive education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive education about the disease, drug therapy, diet, and telephonic strengthening
Study: 8607955
Drug: Antibiotic ear
Normalized name: Antibiotic Ear
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ear drops (suspension of polymyxin B sulfate, neomycin sulfate, and hydrocortisone)
Study: 6208248
Drug: neomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: neomycin (1 g/l) + bacitracin (50,000 IU/l) + clindamycin (900 mg/l)
Study: 6208248
Drug: mezlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (4 g) + oxacillin (2 g) intravenously
Study: 6208248
Drug: no antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: no antibiotics
Study: 29913743
Drug: Standard Gynecological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Gynecological Treatment + Mensendieck Somatocognitive Therapy (MSCT)
Study: 29913743
Drug: Standard Gynecological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Gynecological Treatment (STGT)
Study: 18337147
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (MgSO4) 0.1 mg/l (4g)
Study: 12056708
Drug: Eniluracil/5-fluorouracil (5-FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniluracil/5-fluorouracil (5-FU) regimen: 5-FU 1 mg/m2 twice daily + eniluracil 10 mg/m2 twice daily for 28 days
Study: 10078606
Drug: TA-GW vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-GW vaccine (300 microg)
Study: 10078606
Drug: TA-GW vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-GW vaccine (0, 3, 30 microg)
Study: 8575575
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg.day‐1 for 4 days)
Study: 8575575
Drug: OKY‐046 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐046 (400 mg.day‐1 for 4 days)
Study: 30542740
Drug: Hydrogen gas
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen gas inhalation for 3 hours/day at home
Study: 26825258
Drug: Drospirenone-containing combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-containing combined oral contraceptives (DRSP)
Study: 22047681
Drug: L-carnitine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 4 g/day + Celecoxib 300 mg/day
Study: 22047681
Drug: L-carnitine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 4 g/day + celecoxib 300 mg/day + megestrol acetate 320 mg/day
Study: 16053010
Drug: Daily renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily renal multivitamin containing folate (FA), vitamin B6 and B12 (5 mg, 10 mg and 0.4 mg respectively)
Study: 16053010
Drug: Supraphysiological daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological daily doses (15 mg, 100 mg and 1 mg)
Study: 7491880
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g fat
Study: 7491880
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g fat
Study: 7491880
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g fat plus 50 g fructose
Study: 7491880
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (36 mg, or 120,000 U retinol)
Study: 1828420
Drug: Amlodipine 1.25
Normalized name: levamlodipine 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 1.25 mg
Study: 1828420
Drug: All amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All amlodipine doses
Study: 1828420
Drug: Amlodipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (all doses)
Study: 6791200
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg haloperidol IM
Study: 22191384
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract (daily oral intake)
Study: 18214607
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 IU) administered subcutaneously 20 to 30 min before ERCP
Study: 18214607
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before ERCP
Study: 18214607
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution 0.5 ml)
Study: 15845568
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) with concurrent carboplatin 30 mg/m² per fraction up to the first 20 fractions.
Study: 12826150
Drug: Simulect (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulect (20 mg, 30 minutes before reperfusion and 4 days after transplantation) and steroids
Study: 10582540
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (VER) administered acutely
Study: 10582540
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (VER) administered intravenously (IV)
Study: 10582540
Drug: Different oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different oral formulations of Verapamil (VER)
Study: 7225473
Drug: Sublingual exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual exposure to allergens
Study: 29649997
Drug: Coaching Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching Group (CoachG; feedback on daily steps, MVPA, total EE with need supportive coaching)
Study: 27646843
Drug: Ricolinostat 160
Normalized name: Ricolinostat
DrugBank: Ricolinostat (DB12376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ricolinostat 160 mg once daily on days 1–21 of a 28 day cycle, in combination with lenalidomide 25 mg and dexamethasone 40 mg.
Study: 18570844
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg diclofenac anal suppository after surgery
Study: 797543
Drug: Active corticosteroid
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active corticosteroid comparison drug
Study: 30781962
Drug: Postoperative continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative continuous lavage (irrigation with saline or another solution over 24-48 hours)
Study: 27796035
Drug: Enhanced medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced medication plan with graphical and textual information on drug handling